Supreme Court Rules Beta Crystalline Form of Imatinib Mesylate Ineligible for Patent Due to Non-Patentability.

Fundamental that for grant of patent the subject must satisfy the twin tests of “invention” and “patentability” - the beta crystalline form of Imatinib Mesylate, fails in both the tests of invention and patentability - SC .....

X X   X X   Extracts   X X   X X

→ Full Text of the Document

X X   X X   Extracts   X X   X X